The incidence and clinical significance of nucleophosmin mutations in childhood AML.
about
Prevalence and prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology GroupHow I treat pediatric acute myeloid leukemiaChildhood acute myeloid leukaemiaPrognostic significance of FLT3-ITD in pediatric acute myeloid leukemia: a meta-analysis of cohort studies.Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia.Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia (AML): a report from the Children's Oncology Group.High-resolution melting curve analysis, a rapid and affordable method for mutation analysis in childhood acute myeloid leukemiaPrognostic significance of nucleophosmin mutations and FLT3 internal tandem duplication in adult patients with cytogenetically normal acute myeloid leukemiaNucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.Leukemic mutations in the methylation-associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children's Oncology GroupDifferences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients: a report from the Children's Oncology Group.Cancer stem cells: impact, heterogeneity, and uncertaintyCorrelation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia.Residual disease detected by multidimensional flow cytometry signifies high relapse risk in patients with de novo acute myeloid leukemia: a report from Children's Oncology Group.Comparative analysis of different approaches to measure treatment response in acute myeloid leukemiaMinimal residual disease detection in pediatric acute myeloid leukemia: does flow cytometry score a point over molecular biology?Measurements of treatment response in childhood acute leukemia.Rapid method for detection of mutations in the nucleophosmin gene in acute myeloid leukemia.Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology GroupProgress of minimal residual disease studies in childhood acute leukemia.High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.Role of nucleophosmin in acute myeloid leukemia.NPMc+ cooperates with Flt3/ITD mutations to cause acute leukemia recapitulating human disease.The role of HOX genes in normal hematopoiesis and acute leukemia.Children's Oncology Group's 2013 blueprint for research: acute myeloid leukemiaOverview of therapy and strategies for optimizing outcomes in de novo pediatric acute myeloid leukemia.Acute myeloid leukemia in infants: biology and treatmentA surrogate marker to detect nucleophosnim (NPM1) gene mutations in the cytoplasm of acute myeloid leukemia (AML) blast cells in 30 adult Iraqi patients.Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.NPM1, FLT3 and CEBPA mutations in pediatric patients with AML from Argentina: incidence and prognostic value.Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.Accurate Medicine: Indirect Targeting of NPM1-Mutated AML.The frequency of NPM1 mutations in childhood acute myeloid leukemia.
P2860
Q24602856-DA2A8B66-5083-4F56-AEA3-2D192171C7DEQ26992280-A2A8B682-6580-4F46-8EB7-1766933B05CEQ27005960-FEC7A072-6A86-4E17-9A76-721A27024ADAQ30248904-A8262198-E7E7-4398-AFE0-CBB96E6545BAQ33555627-79A87467-4E84-4D82-B591-D752F1F118E2Q33754603-7C9580E5-4F7A-4CAA-81E9-E223D05BB326Q33872395-2706CB7A-9C8A-45B4-B2BC-56CF18887250Q34052581-355F5135-14ED-40A3-BEC4-5659E9CA5BD2Q34154213-5CADC2C1-5574-4AA0-8D59-738C5358801FQ34316768-8DD75257-0274-41F8-AE9F-10244118EAFFQ34755985-139396DF-35C1-4E0D-A025-A4B19D1394BCQ34764504-06613F7E-066F-4C4E-811B-5BC2620E9F37Q35046171-F30BBC62-7C0E-40BA-B073-4216EAF9845DQ35430146-0C1A2598-4E7D-4F79-BA8D-9CD8A599E0F2Q35857599-FB2EA876-BD8F-4EBB-A295-B170E24F74F3Q35909648-3DEF2B4F-9F55-4CED-ACC0-3F9030225B7EQ36053792-B852F421-2727-461E-8805-9F01AE464727Q36194222-BBC57125-6FE4-49FF-AF24-46F4F01259B8Q36290737-D123FD2E-081E-4CF2-B3D9-FD6CC8043133Q36508284-EE3BD1D8-EAA1-4F56-88FD-624A1148CF2CQ36513773-8AE1032E-ECB8-4590-B50E-9996D319BEFFQ36734631-15B084EE-BB2D-4426-AAEE-8CCF55FD04DDQ36739522-56D0A073-7EA5-4495-A751-1967CFFBB230Q36805474-342645A9-7F4F-4164-A93D-4676DB6D823DQ36981845-735F861B-7347-4C35-88E1-F3780515E607Q37125803-73D51916-73EC-448E-ACC1-39E75B4FCAF2Q37185272-4E673BBD-CE2B-48CD-B3BE-201CBF0B6918Q37598941-AF316B92-E297-4E7A-A70C-064E23D11819Q37599556-EF32381E-83EE-4049-A6B3-3E908D3F3B01Q38065068-A75C5CDB-04E3-47C8-9628-F912E7A5438AQ38068816-821A4419-EB35-4D14-A541-B839B34AFCB1Q38196743-F7D124D1-B083-4815-BE70-03DB2FDA14B3Q38479156-B158EC3C-99AE-4E9E-B7E0-8DCB22B79C5AQ39274623-D19F3618-E82F-4478-B950-1511F933D15FQ39450821-2E4D81D4-BFF7-40B0-A46B-AB6D9AD359AEQ40100589-92661DBD-52C3-4A79-8DC7-514D6426172BQ40519542-05E52A23-281A-4F2D-9ECC-55E3AF012CA1Q40781300-26E79763-59C0-4E8E-BBF6-878E02BEC981Q41636372-8F1ED31E-0311-4971-A482-AF59C40058E6Q41704381-5B76F56D-26A2-4FAA-9B27-6D97F84D1F90
P2860
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@ast
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@en
type
label
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@ast
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@en
prefLabel
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@ast
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@en
P2093
P2860
P1433
P1476
The incidence and clinical significance of nucleophosmin mutations in childhood AML.
@en
P2093
Donald Small
Emily McIntyre
Myron Chang
Norman Lacayo
Patrick Brown
Rachel Rau
Robert J Arceci
Soheil Meshinchi
Todd A Alonzo
P2860
P304
P356
10.1182/BLOOD-2007-02-076604
P407
P577
2007-04-17T00:00:00Z